Form 4: Rigel Pharmaceuticals Executive Stock Disposition

Raymond J. Furey, EVP and General Counsel of Rigel Pharmaceuticals, disposed of 877 shares of common stock to cover tax obligations.

Summary

• Raymond J. Furey, EVP, GC, CCO & Corp Sec of Rigel Pharmaceuticals, Inc. (RIGL), reported the disposition of 877 shares of common stock.
• The transaction occurred on June 1, 2026, at a price of $29.86 per share.
• The disposition was executed via code 'F', indicating the payment of tax liability by delivering or withholding securities incident to the vesting of a security.
• Following this transaction, the reporting person maintains beneficial ownership of 50,936 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax-related transaction rather than a change in management sentiment or company outlook.

Positives

• The transaction was a routine administrative action related to tax withholding upon the vesting of equity awards, rather than a discretionary market sale.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a routine administrative disclosure common in the biotechnology sector, where executives frequently receive equity-based compensation that triggers tax withholding events upon vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.
• The use of 'Code F' for tax withholding is a standard industry practice for publicly traded companies to satisfy statutory tax obligations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Executive Compensation, Stock Disposition